Trials / Recruiting
RecruitingNCT07223333
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study of Single Ascending Doses in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of PATAS
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- AdipoPharma LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PATAS Trifluoroacetate | A drug targeting the interaction between the ALMS1 protein and alpha-PKC |
| DRUG | Placebo | Excipient only formulation, without active compound |
Timeline
- Start date
- 2026-01-27
- Primary completion
- 2026-07-30
- Completion
- 2026-09-30
- First posted
- 2025-10-31
- Last updated
- 2026-02-23
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07223333. Inclusion in this directory is not an endorsement.